“What’s unique about these new classes of drugs is that they’re not glucose-lowering drugs. They’re cardio-renal risk-reducing agents that happen to lower glucose if your kidney function is normal or reasonable,” said George Bakris, MD, who will present during the symposium, which begins at 4:30 p.m. CT on Monday.
Up next: Breakthrough drug advances offer promise of improved DKD therapeutic options
